Navigation Links
Repligen Elects Glenn L. Cooper, M.D. to the Board of Directors
Date:8/25/2009

WALTHAM, Mass., Aug. 25 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that Glenn L. Cooper, M.D. has been elected to its Board of Directors. Dr. Cooper has extensive leadership experience in the pharmaceutical and biotechnology industries with expertise in transforming development stage companies into commercial organizations. Dr. Cooper was formerly the Chairman and Chief Executive Officer of Indevus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on urology and endocrinology. Under his tenure, Indevus grew from a 25-employee development stage company to a fully integrated pharmaceutical organization with five marketed products, over $100 million in annual sales, and an advanced clinical pipeline. Indevus was acquired by Endo Pharmaceuticals, Inc. in March 2009.

"Dr. Cooper's clinical background and proven business acumen make him an ideal addition to Repligen's Board of Directors," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen. "Through his experience at Indevus, he will provide us with strategic leadership and guidance as we develop innovative products and work to build a sustainable biopharmaceutical company."

Prior to joining Indevus in 1993, Dr. Cooper held numerous executive level positions, including President and Chief Executive Officer of Progenitor, Inc., Executive Vice President and Chief Operating Officer of Sphinx Pharmaceuticals Corporation, and various clinical and regulatory positions with Eli Lilly. Dr. Cooper has participated in the development, approval and commercialization of numerous drugs, including Prozac((R)), Axid((R)), Lorabid((R)), Ceclor((R)), SANCTURA((R)), SANCTURA XR((R)), Supprelin-LA((R)), and Vantas((R)). Dr. Cooper received an M.D. from Tufts University School of Medi
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... YORK , July 27, 2015 ... today announced the winners of its annual Klerman ... research by scientists who have been supported by ... career scientists to pursue innovative ideas in neurobiological ... "proof" of concept for the early detection, treatment, ...
(Date:7/27/2015)... , July 27, 2015 IDEXX Laboratories, ... than 8,000 clinics have submitted over 100,000 specimens to ... in just the first 10 days since the breakthrough ... disease (CKD) is a leading cause of suffering and ... submitted specimens are consistent with generally accepted kidney disease ...
(Date:7/26/2015)... ... July 26, 2015 , ... ... VALIDATE® ANEMIA calibration verification / linearity test kit. The VALIDATE® ANEMIA kit contains ... ANEMIA kit is prepared using the CLSI recommended “equal delta” method for linearity ...
(Date:7/24/2015)... 24, 2015 Ryan & Maniskas, LLP ... States District Court for the Northern District of ... that purchased the common stock of Avalanche Biotechnologies, Inc. ("Avalanche" ... 2014 and June 15, 2015, inclusive (the "Class Period"). ... move the Court for appointment as a lead plaintiff of ...
Breaking Biology Technology:Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3
... ExL Pharma, Cision and the PRSA have,joined together ... relations executives the first Pharmaceutical Public Relations,Symposium in ... event will cover the key issues and challenges ... under ongoing political and media scrutiny,most notably as ...
... pharma industry is,not at a standstill: it has changed ... companies, profits, biological drugs are,now making their presence felt. ... impact, biologicals are providing the current focus for novel,discovery. ... rules,for their development are different and they are often ...
... (Nasdaq: JAZZ ) announced today that Nathaniel M.,Zilkha has ... 2007. The Company also announced that Adam H. Clammer has,resigned ... Mr. Zilkha is a Principal at Kohlberg Kravis Roberts & ... industry team. Prior to joining KKR,earlier this year, Mr. Zilkha ...
Cached Biology Technology:Leading Pharmaceutical Communication Executives Gather for the 1st Annual Pharmaceutical Public Relations Symposium 2Updated Drug Development Scrip Report Responds to the Pharma Industry's Major Changes 2
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... PA, February 20, 2013 A study published in the ... has determined that there is increasing evidence of a connection ... and dairy products, and that medical nutrition therapy (MNT) can ... 17 million Americans suffer from acne, mostly during their adolescent ...
... 2013) New findings by Columbia researchers suggest ... may be a second necessary factor for the development ... Alzheimer,s disease focus on the accumulation of amyloid plaque ... for Research on Alzheimer,s Disease and the Aging Brain, ...
... Identifying areas of malarial infection risk depends ... average monthly temperatures, according to a team of ... apply to environmentally temperature-dependent organisms other than the ... of several of the essential mosquito and parasite ...
Cached Biology News:Increasing evidence links high glycemic index foods and dairy products to acne 2New approach alters malaria maps 2
HSPBP1 Antibody...
... RACE (rapid amplification of cDNA ends) technique ... 5' and 3' cDNA ends. The GeneRacer ... Transcriptase (RT) for improved amplification of the ... mRNA. The RNase H portion of SuperScript ...
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Reactivity: Human...
Biology Products: